Bionano Genomics, INC Form 4 insider transactions

Mark Adamchak, Principal Accounting Officer of Bionano Genomics, Inc., received 5,000 shares of common stock on August 3, 2026.

Jonathan Dixon V., General Counsel of Bionano Genomics, Inc., received 15,000 shares of common stock on August 3, 2026.

Mark Oldakowski, Chief Operating Officer of Bionano Genomics, Inc., received 15,000 shares of common stock on August 3, 2026.

Alex Reid Hastie, Chief Scientific Officer of Bionano Genomics, Inc., received 54,000 shares of common stock on August 3, 2026.

General Counsel Jonathan V. Dixon reported the withholding of 24 shares of Bionano Genomics common stock to satisfy tax obligations.

Bionano Genomics Chief Operating Officer Mark Oldakowski disposed of 27 shares to satisfy tax obligations related to RSU vesting.

Chief Medical Officer Alka Chaubey reported the withholding of 24 shares to satisfy tax obligations related to RSU vesting.

Principal Accounting Officer Mark Adamchak reported the withholding of 7 shares of common stock to satisfy tax obligations related to an RSU award.

Director Aleksandar Rajkovic was granted 9,149 stock options in Bionano Genomics as part of standard equity compensation.

Director Yvonne Linney was granted 9,149 stock options in Bionano Genomics, Inc. as part of equity compensation.

Director Kristiina Vuori was granted 9,149 stock options in Bionano Genomics, Inc. as part of standard equity compensation.

Director Christopher J. Twomey was granted 9,149 stock options in Bionano Genomics, Inc. as part of equity incentive compensation.

Director David L. Barker was granted 9,149 stock options in Bionano Genomics, Inc. as part of standard equity compensation.

Mark Adamchak, Principal Accounting Officer at Bionano Genomics, was granted 10,890 stock options with an exercise price of $1.27.

Bionano Genomics' Chief Medical Officer, Alka Chaubey, was granted 27,737 stock options with an exercise price of $1.27.

Bionano Genomics' Chief Operating Officer, Mark Oldakowski, was granted 27,737 stock options with an exercise price of $1.27, vesting over four years.

Bionano Genomics' General Counsel, Jonathan V. Dixon, was granted 26,117 stock options with an exercise price of $1.27, vesting over four years.

Bionano Genomics' President and CEO, R. Erik Holmlin, was granted 69,484 stock options with an exercise price of $1.27, vesting over four years.

Bionano Genomics' COO, Mark Oldakowski, reported the withholding of 59 common shares for tax obligations related to a vested RSU award.

Bionano Genomics' Chief Operating Officer, Mark Oldakowski, reported the future withholding of 59 common shares on September 11, 2025, to cover tax obligations from a vested RSU award.

Bionano Genomics' Chief Medical Officer, Alka Chaubey, reported the withholding of 51 shares of common stock for tax obligations related to an RSU award vesting on September 11, 2025.

Bionano Genomics, Inc. Director Christopher J. Twomey was granted 2,775 stock options with an exercise price of $3.67, vesting over 12 months.

Bionano Genomics, Inc. director Kristiina Vuori, MD, was granted 2,775 stock options with an exercise price of $3.67, aligning her interests with shareholders.

Bionano Genomics, Inc. Director Yvonne Linney was granted 2,775 stock options with an exercise price of $3.67, vesting over 12 months.

Bionano Genomics, Inc. Director Albert Luderer was granted 2,775 stock options with an exercise price of $3.67, vesting over 12 months.

Bionano Genomics, Inc. Director David L. Barker was granted 2,775 stock options with an exercise price of $3.67, vesting over 12 months.

Bionano Genomics, Inc. director Hannah Mamuszka was granted 2,775 stock options with an exercise price of $3.67, vesting over 12 months or upon the next annual stockholder meeting.

Bionano Genomics, Inc. has reported that Director Aleksandar Rajkovic was granted 2,775 stock options with an exercise price of $3.67 per share, vesting over 12 months.

Bionano Genomics' Chief Operating Officer, Mark Oldakowski, reported the withholding of 27 shares of common stock by the company to cover tax obligations related to a vested RSU award.

Bionano Genomics' Principal Accounting Officer, Mark Adamchak, reported the disposition of 7 shares of common stock valued at $3.69 per share to satisfy tax withholding obligations related to the vesting of a restricted stock unit award.